RemeGen CoREGMF -6.23%41 Interest Coverage is 49.38 as of Dec. 2025, which is 67% above its 10-year median of 29.59. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $18.62 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, RemeGen Co ranks worse than 68.17% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. RemeGen Co's
Operating Income
for the
three
months ended in Dec. 2025 was $92.1 Mil. RemeGen Co's Interest Expense for the
three
months ended in Dec. 2025 was $-1.9 Mil.
RemeGen Co's interest coverage for the quarter that ended in Dec. 2025 was 49.38.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for RemeGen Co's Interest Coverage or its related term are showing as below:
REGMF'
s Interest Coverage Range Over the Past 10 Years
Min: 2.23 Med: 29.59 Max: 56.94
Current: 19.96
REGMF's Interest Coverage is ranked worse than 68.17% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs REGMF: 19.96
RemeGen Co (OTCPK:REGMF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
RemeGen Co Interest Coverage Related Terms
RemeGen Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
REGMF vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, RemeGen Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (REGMF) has a Interest Coverage of 49.38 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on RemeGen Co and its competitors. This is 67% above median its historical median of 29.59. Over the past decade, RemeGen Co's Interest Coverage has ranged from 2.23 to 56.94. According to the industry distribution chart, RemeGen Co ranks #257 out of 377 companies in the Biotechnology industry, placing it in the top 68.2%.
Is RemeGen Co's Interest Coverage too high?
RemeGen Co's current Interest Coverage of 49.38 is 67% above median its 10-year median of 29.59. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 56.94. The Biotechnology industry median Interest Coverage is 106.07. RemeGen Co's value of 49.38 is 53.4% below this industry median. Based on the distribution chart, RemeGen Co ranks #257 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #257 out of 377 companies for Interest Coverage. This places RemeGen Co in the lower half of its industry. The industry median Interest Coverage is 106.07. RemeGen Co's value of 49.38 is 53.4% below this benchmark. Historically, RemeGen Co's own Interest Coverage has ranged from 2.23 to 56.94 over the past decade. While the company's 10-year median is 29.59 vs. the industry median of 106.07, RemeGen Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Interest Coverage of 49.38 is 53.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Interest Coverage is 49.38, which is 67% above median its own 10-year median of 29.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $18.62, compared to a current price of $12.05 — trading 35.3% below its estimated fair value. The current Interest Coverage is 49.38, which is 67% above median its 10-year median of 29.59 and 53.4% below the Biotechnology industry median of 106.07. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For RemeGen Co (REGMF), the current Interest Coverage is 49.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (REGMF) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of $12.05 is trading 35.3% below its estimated GF Value™ of $18.62.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for REGMF:
Interest Coverage: 49.38 (67% above median its 10-year median of 29.59)
GF Value™: $18.62 vs. price of $12.05 (35.3% below fair value)
Industry Position: 53.4% below the Biotechnology median (#257 of 377)
No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for REGMF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REGMF has been successfully added to your 
